MG risk, immune system have complex two-way connection: Study
Circulating inflammatory molecules called cytokines may be associated with a risk for developing myasthenia gravis, a recent study suggests.| Myasthenia Gravis News
Circulating inflammatory molecules called cytokines may be associated with a risk for developing myasthenia gravis, a recent study suggests.| Myasthenia Gravis News
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
Zilbrysq was found safe and effective in a clinical trial for generalized myasthenia gravis patients who switched from other C5 inhibitors.| Myasthenia Gravis News
Thymectomy led to a long-term reduction in the levels of immune T-cells and to temporary changes in cytokine levels in MG patients.| Myasthenia Gravis News
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
Study data show long-term treatment with Zilbrysq led to sustained reductions in disease severity in generalized myasthenia gravis patients.| Myasthenia Gravis News
Treatment with nipocalimab in gMG patients led to significant reductions in disease severity, per top-line data from a pivotal Phase 3 trial.| Myasthenia Gravis News
Researchers say the case suggests Vyvgart can be an alternative drug for achieving minimal manifestation status during a myasthenic crisis.| Myasthenia Gravis News
More than half of MG patients in a study had fatigue and its severity correlated with disease worsening, crises, and delays in diagnosis.| Myasthenia Gravis News
Rituximab is an antibody-based therapy that may be used off-label in patients with certain types of myasthenia gravis.| Myasthenia Gravis News
A 64-year-old woman with dropped head syndrome was found to have a form of MG with antibodies against MuSK, and weak spine muscles.| Myasthenia Gravis News
Rituximab isn't officially approved for MG, but is used off-label when standard treatments fail, such as patients with anti-MuSK antibodies.| Myasthenia Gravis News
An open-label, multicenter Phase 2 clinical trial will test KYV-101 in people with refractory MG and positive for self-reactive antibodies.| Myasthenia Gravis News
Vyvgart is an approved infusion treatment for adults with generalized myasthenia gravis who are AChR-antibody positive.| Myasthenia Gravis News
Rystiggo is a myasthenia gravis treatment for adults with generalized MG. It's administered as an injection.| Myasthenia Gravis News
Getting a correct myasthenia gravis diagnosis may require a series of blood, nerve, muscle, and imaging tests.| Myasthenia Gravis News
Fatigue linked to myasthenia gravis can affect a person’s quality of life, but there are coping strategies that can be used to minimize it.| Myasthenia Gravis News
Treatment with telitacicept for almost six months lessened disease activity in gMG adults positive for anti-AChR antibodies, per a study.| Myasthenia Gravis News
Soliris (eculizumab) is an infusion therapy approved for treating adults with generalized myasthenia gravis.| Myasthenia Gravis News
Muscle weakness and fatigue are hallmark symptoms of myasthenia gravis (MG), an autoimmune disorder. MG symptoms may come and go.| Myasthenia Gravis News
Thymectomy removes the thymus gland, aiming to cause remission from myasthenia gravis symptoms and a decrease in the need for medications.| Myasthenia Gravis News
Plasmapheresis is a treatment for myasthenia gravis, commonly used during a myasthenic crisis and in preparation for thymectomy.| Myasthenia Gravis News
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept for generalized myasthenia gravis.| Myasthenia Gravis News
The anti-malaria drug dihydroartemisinin, known as DHA, showed promise for treating myasthenia gravis in a rat model of MG, per a new study.| Myasthenia Gravis News
Soliris effectively eased symptoms and reduced the need for other medications in adults with MG in a clinical practice setting, data show.| Myasthenia Gravis News
Having a thymectomy was found to significantly ease neurological symptoms in MG patients older than 65 with a thymus tumor, per a new study.| Myasthenia Gravis News
Scientists have identified a set of inflammatory molecules that could be useful as biomarkers to aid in MG diagnosis and classification.| Myasthenia Gravis News
Myasthenia gravis is a neuromuscular disease characterized by weakness and fatigue that can affect muscles involved in voluntary movements.| Myasthenia Gravis News
